FindTrial
Sign In

Anti-thrombotic strategies for patients with aspirin intolerance after percutaneous coronary intervention: a registry study

Anti-thrombotic strategies for patients with aspirin intolerance after percutaneous coronary intervention: a registry study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300067274
Enrollment
Unknown
Registered
2023-01-03
Start date
2023-02-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aspirin intolerance

Interventions

Aspirin group:NA
Indobufen group:NA

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Receiving PCI in Zhongshan Hospital; 2. Aged 18-90 years; 3. Receiving DAPT after PCI; 4. Participating in the study voluntarily and obtaining informed consent.

Exclusion criteria

Exclusion criteria: 1. In-hospital death; 2. Receiving cilotazole-based DAPT; 3. Receiving anticoagulant drugs at the same time; 4, Suffering from platelet disease; 5. Patients considered unsuitable for this study by the investigators.

Design outcomes

Primary

MeasureTime frame
Major cardiovascular and cerebrovascular adverse events;BACR bleeding events;—

Secondary

MeasureTime frame
All-cause death;Cardiovascular death;Recurrent myocardial infarction;Repeat revascularization;Stroke;In-stent thrombosis;—

Countries

China

Contacts

Public ContactQian Juying

Zhongshan Hospital, Fudan University

qian.juying@zs-hospital.sh.cn+86 136 6181 3201

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026